[ad_1]
BERLIN: Pharmaceutical company AstraZeneca has agreed to supply 9 million additional doses of its coronavirus vaccine to the European Union during the first quarter, the bloc’s executive arm said Sunday.
The new target of 40 million doses by the end of March is still only half what the British-Swedish company had originally aimed for, triggering a spat between AstraZeneca and the EU last week.
European Commission President Ursula von der Leyen said after a call with seven vaccine makers Sunday that AstraZeneca will also begin deliveries one week sooner than scheduled and expand its manufacturing capacity in Europe.
“Step forward on vaccines,” tweeted Von der Leyen, who has come under intense pressure over the European Commission’s handling of the vaccine orders in recent days.
The EU is far behind Britain and the United States in getting its population of 450 million vaccinated against the virus. The slow rollout has been blamed on a range of national problems as well as delayed authorization of the vaccines compared to elsewhere and an initial shortage of supply.
The announcement last week that AstraZeneca would initially only supply 31 million doses to the EU’s 27 member states due to production problems triggered a fierce dispute between the two sides, with officials in Brussels saying they feared the company was treating the bloc unfairly compared to other customers, such as the United Kingdom.
On Friday, hours after regulators authorized the vaccine for use across the EU, the commission announced that it was tightening rules on exports of Covid-19 vaccines, sparking an angry response from Britain. The commission has since made clear the new measure will not trigger controls on vaccines shipments produced in the 27-nation bloc to the small territory that is part of the United Kingdom bordering EU member Ireland.
Under the post-Brexit deal, EU products should still be able to travel unhindered from the bloc to Northern Ireland.
EU member states praised the bloc’s executive branch last year for signing numerous deals with vaccine makers, saying the joint purchase using combined market weight of the entire bloc had ensured a fair distribution for all 27 countries at good prices.
In a statement, the European Commission said it plans to set up an specialized body to improve the bloc’s response to health emergency and “deliver a more structured approach to pandemic preparedness.”
As part of the effort, together with industry, the EU said it will “fund design and development of vaccines and scale up manufacturing in the short and medium term, and also to target the variants of Covid-19.”
“The pandemic highlighted that manufacturing capacities are a limiting factor,” it said. “It is essential to address these challenges.”
The new target of 40 million doses by the end of March is still only half what the British-Swedish company had originally aimed for, triggering a spat between AstraZeneca and the EU last week.
European Commission President Ursula von der Leyen said after a call with seven vaccine makers Sunday that AstraZeneca will also begin deliveries one week sooner than scheduled and expand its manufacturing capacity in Europe.
“Step forward on vaccines,” tweeted Von der Leyen, who has come under intense pressure over the European Commission’s handling of the vaccine orders in recent days.
The EU is far behind Britain and the United States in getting its population of 450 million vaccinated against the virus. The slow rollout has been blamed on a range of national problems as well as delayed authorization of the vaccines compared to elsewhere and an initial shortage of supply.
The announcement last week that AstraZeneca would initially only supply 31 million doses to the EU’s 27 member states due to production problems triggered a fierce dispute between the two sides, with officials in Brussels saying they feared the company was treating the bloc unfairly compared to other customers, such as the United Kingdom.
On Friday, hours after regulators authorized the vaccine for use across the EU, the commission announced that it was tightening rules on exports of Covid-19 vaccines, sparking an angry response from Britain. The commission has since made clear the new measure will not trigger controls on vaccines shipments produced in the 27-nation bloc to the small territory that is part of the United Kingdom bordering EU member Ireland.
Under the post-Brexit deal, EU products should still be able to travel unhindered from the bloc to Northern Ireland.
EU member states praised the bloc’s executive branch last year for signing numerous deals with vaccine makers, saying the joint purchase using combined market weight of the entire bloc had ensured a fair distribution for all 27 countries at good prices.
In a statement, the European Commission said it plans to set up an specialized body to improve the bloc’s response to health emergency and “deliver a more structured approach to pandemic preparedness.”
As part of the effort, together with industry, the EU said it will “fund design and development of vaccines and scale up manufacturing in the short and medium term, and also to target the variants of Covid-19.”
“The pandemic highlighted that manufacturing capacities are a limiting factor,” it said. “It is essential to address these challenges.”
[ad_2]
Source link
